The dual inhibitor of mutant IDH1/2 enzymes, vorasidenib, received approval in the USA for the treatment of low-grade astrocytoma or oligodendroglioma with IDH1/2 mutations in 2024 [51]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).